image credit: Unsplash

Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’

June 24, 2021

In a joint statement with Aduhelm (aducanumab) development partner Eisai, Biogen said it is expecting slow take-up of the drug and an eligible patent population of around 1-2 million people with mild Alzheimer’s in the US, saying it has no data on more advanced cases.

If its assumptions are wrong, “we stand ready to work with public and private payers to address pricing in order to achieve both patient access and support budget sustainability,” said the companies.

Read More on Pharmaphorum